Haberland, Annekathrin
Müller, Johannes
Wallukat, Gerd
Wenzel, Katrin
Funding for this research was provided by:
Berlin Cures Holding AG
Article History
Received: 23 February 2018
Revised: 2 May 2018
Accepted: 29 May 2018
First Online: 11 June 2018
Compliance with ethical standards
: The use of human eluate material from the regeneration of IgG immunoadsorption columns of patients treated at the Deutsches Herzzentrum Berlin, Berlin, Germany, for autoantibody research had been approved by the Human Ethics Committee of the Humboldt University of Berlin (Berlin, Germany). Donors signed an informed consent form [CitationRef removed].
: Annekathrin Haberland, Johannes Müller, Gerd Wallukat, and Katrin Wenzel are employed by Berlin Cures. Johannes Müller, Gerd Wallukat, and Annekathrin Haberland are shareholders of the Berlin Cures Holding AG, the parent company of the Berliner branch Berlin Cures GmbH. Berlin Cures develops BC 007, a DNA-based therapeutic drug for the neutralisation of heart-specific autoantibodies. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject or materials discussed in the manuscript apart from those which are disclosed. The authors declare that they have no competing interests.